Shares of US clinical-stage biopharma firm Dynavax Technologies (Nasdaq: DVAX) took a 63% nosedive in Monday morning’s trading after bad news on its hepatitis B vaccine.
Chief executive Eddie Gray admitted that the company might not be able to advance Heplisav-B (hepatitis B vaccine, recombinant (adjuvanted)) alone and quickly needed to find a partner to continue the program, after the receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA).
The CRL, relating to Dynavax’s Biologics License Application for Heplisav-B, seeks information regarding several topics, including clarification regarding specific adverse events of special interest (AESIs).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze